SCHEMBL17434601

SCHEMBL17434601

Ic1ccc(COC2COC(c3ccccc3)OC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.42
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSK P43235 1/20 0.37
NAAA Q02083 3/20 0.37
CYP3A4 P08684 2/20 0.36
IDO1 P14902 2/20 0.36
SLC18A3 Q16572 2/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560842 0.89 CTSL (0.45) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11637675 0.89 CTSL (0.45) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11635684 0.89 CTSL (0.45) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11632428 0.85 NAAA (0.42) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11633899 0.85 SLC18A3 (0.48) NAAASLC18A3
SCHEMBL11632425 0.85 NAAA (0.42) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11634473 0.85 MEN1 (0.42) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL16600197 0.85 FABP7 (0.40) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11634478 0.85 MEN1 (0.42) MEN1CYP2C19KMT2ACTSLCTSB
SCHEMBL11633902 0.85 SLC18A3 (0.48) NAAASLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2975022-B1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-05-08 EP disclosed
EP-2975022-B1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-05-08 EP disclosed
US-9862676-B2 Hydroxamic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2018-01-09 US disclosed
US-9862676-B2 Hydroxamic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2018-01-09 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2016-02-11 US disclosed
EP-2975022-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2016-01-20 EP disclosed
EP-2975022-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2016-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039751-A1 NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF H1-0, H1-2, HDAC1 APP 4735/4885MEN1 1824/4885CYP2C19 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.